Nuvalent, Inc. (NUVL): Price and Financial Metrics


Nuvalent, Inc. (NUVL): $32.46

-0.62 (-1.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NUVL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NUVL Stock Price Chart Interactive Chart >

Price chart for NUVL

NUVL Price/Volume Stats

Current price $32.46 52-week high $40.43
Prev. close $33.08 52-week low $7.09
Day low $32.12 Volume 78,420
Day high $33.40 Avg. volume 165,406
50-day MA $30.93 Dividend yield N/A
200-day MA $19.71 Market Cap 1.83B

Nuvalent, Inc. (NUVL) Company Bio


Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.


NUVL Latest News Stream


Event/Time News Detail
Loading, please wait...

NUVL Latest Social Stream


Loading social stream, please wait...

View Full NUVL Social Stream

Latest NUVL News From Around the Web

Below are the latest news stories about NUVALENT INC that investors may wish to consider to help them evaluate NUVL as an investment opportunity.

Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 7:30 a.m. PT in San Francisco.

Yahoo | January 4, 2023

Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?

Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.

Yahoo | January 2, 2023

Nuvalent Looks Overvalued After A Rapid Rally

Nuvalent, Inc. has attracted market interest, while headwinds have put the entire biotech sector under upward pressure. Read why NUVL is overvalued.

Seeking Alpha | December 14, 2022

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent's approach to rationally targeting ROS1. NVL-520 is currently being studied in the ongoing ARROS-1 Phase 1/2 clinical tri

Yahoo | December 13, 2022

12 Best Small-Cap Healthcare Stocks To Buy Now

In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […]

Yahoo | December 12, 2022

Read More 'NUVL' Stories Here

NUVL Price Returns

1-mo 14.18%
3-mo -8.15%
6-mo 118.44%
1-year 160.30%
3-year N/A
5-year N/A
YTD 9.00%
2022 56.41%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6452 seconds.